HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Gross Margin
- Gross margin · 12 months: Value 75.42%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 75.42% | Gross profit / revenue. Period ending 2026-06-30. $723.99M ÷ $959.90M × 100 ≈ 75.42% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 723.99M USD | Gross Profit |
| Revenue | 959.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 235.91M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $723.99M | $959.90M | $235.91M | 75.42% |
| 2026-03-31 | $688.25M | $899.11M | $210.86M | 76.55% |
| 2025-12-31 | $670.11M | $868.45M | $198.34M | 77.16% |
| 2025-09-30 | $641.74M | $825.94M | $184.21M | 77.70% |
| 2025-06-30 | $605.19M | $772.53M | $167.33M | 78.34% |
| 2025-03-31 | $583.53M | $744.85M | $161.32M | 78.34% |
| 2024-12-31 | $557.92M | $714.73M | $156.81M | 78.06% |
| 2024-09-30 | $536.32M | $681.88M | $145.56M | 78.65% |
| 2024-06-30 | $521.03M | $656.11M | $135.08M | 79.41% |
| 2024-03-31 | $489.57M | $617.51M | $127.94M | 79.28% |
| 2023-12-31 | $460.79M | $582.02M | $121.24M | 79.17% |
| 2023-09-30 | $436.95M | $541.92M | $104.97M | 80.63% |
| 2023-06-30 | $403.22M | $498.86M | $95.63M | 80.83% |
| 2023-03-31 | $382.12M | $471.67M | $89.55M | 81.02% |
| 2022-12-31 | $354.37M | $437.86M | $83.48M | 80.93% |
| 2022-09-30 | $326.35M | $400.76M | $74.41M | 81.43% |
| 2022-06-30 | $298.23M | $364.29M | $66.06M | 81.87% |
| 2022-03-31 | $271.25M | $331.08M | $59.83M | 81.93% |
| 2021-12-31 | $249.92M | $305.44M | $55.52M | 81.82% |
| 2021-09-30 | $222.90M | $270.51M | $47.62M | 82.40% |
| 2021-06-30 | $194.49M | $235.39M | $40.91M | 82.62% |
| 2021-03-31 | $164.90M | $199.58M | $34.67M | 82.63% |
| 2020-12-31 | $132.00M | $159.74M | $27.74M | 82.64% |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | $4.42M | $6.00M | $1.58M | 73.69% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |